Welcome to the e-CCO Library!

DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mengfan Li
Created: Friday, 14 July 2023, 2:22 PM
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Li, M.(1)*;Dong, Y.(1);Zhang, K.(1);Ma, J.(1);He, L.(1);Wei, J.(1);Jiang, J.(1);Zhao, Q.(1);Zhao, Q.(1);Cao, H.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP35: Increasing incidence of pouchitis among patients undergoing ileal pouch-anal anastomosis between 1996 and 2018: A population-based Danish cohort study
Year: 2022
Source: ECCO'22
Authors: Barnes, E.(1);Allin, K.(2);Iversen, A.(2);Herfarth, H.(1);Jess, T.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. S. Choung*1, F. Petralia2, J. Torres3,4, T. Sato5, X-j. Li6, P. Wang2, S. Telesco5, C. Porter7, R. Laird7, R. Gutierrez7, F. Princen6, S. Plevy5, R. Strauss5, M. Riddle7, J. Murray1, J. F. Colombel3, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) Study Group1

Created: Friday, 22 February 2019, 9:41 AM
DOP35: Monitoring of mucosal T cells subsets under biotherapies in IBD: Responders exhibit a phenotype similar to healthy controls
Year: 2020
Source: ECCO'20 Vienna
Authors: Nassim Hammoudi
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP35: Spatial transcriptomics reveals cellular niches associated with histological inflammation in postoperative Crohn’s Disease
Year: 2024
Source: ECCO'24 Stockholm
Authors: Battat, Robert
Created: Tuesday, 30 April 2024, 5:03 PM
DOP36 Family-specific host genetic and gut microbial signatures have a beneficial role in early identification of familial inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.Y. SHIN1, Y.M. Park1, E. Ha2, K.N. Gu2, K. Kim2, C.K. Lee1, H.J. Kim1

Created: Thursday, 30 January 2020, 10:12 AM
DOP36: Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study
Year: 2022
Source: ECCO'22
Authors: Sallette, M.(1);Bouhnik, Y.(2);Nachury, M.(3);Bellanger, C.(4);Laharie, D.(5);Amiot, A.(6);Peyrin-Biroulet, L.(7);Roblin, X.(8);Altwegg, R.(9);Buisson, A.(10);Reenaers, C.(11);Bouguen, G.(12);Vuitton, L.(13);Bourreille, A.(14);Gilletta, C.(15);Serrero, M.(16);Hébuterne, X.(17);Filippi, J.(18); Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
Created: Friday, 11 February 2022, 3:52 PM
DOP36: Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Braun1, A. Di Segni1, M. BenShoshan1, S. Neuman1, O. Picard1, K. Sosnovski1, G. Efroni1, B. Weiss1, D. Yablecovitch1, A. Lahat1, R. Eliakim1, U. Kopylov1, S. Ben-Horin1, Y. Haberman*1,2, Israeli IBD Research Nucleus (IIRN)1

Created: Friday, 22 February 2019, 9:41 AM
DOP36: Gut microbial variations in patients with quiescent Crohns disease predict subsequent disease flare
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Yael Haberman
Created: Tuesday, 28 May 2019, 3:32 PM
Microbiota, Crohn’s disease, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Prognosis, Microbiota
Files: 1
DOP36: Non-invasive assessment of postoperative disease recurrence in Crohn’s Disease: A multicenter, prospective cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Furfaro, F.(1);Zilli , A.(1);Craviotto, V.(1);Aratari , A.(2);Bezzio, C.(3);Gilardi, D.(1);D'Amico, F.(1);Saibeni, S.(3);Papi, C.(2);Peyrin-Biroulet, L.(4);Fiorino, G.(5);Danese, S.(5);Allocca, M.(5)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Laura Francesca Pisani
Created: Friday, 14 July 2023, 2:22 PM
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pisani, L.F.(1,2)*;Crespi, G.(3,4);Mellai, M.(4,5);Flavio, C.(6,7);Annunziata, M.L.(8);Manfredi, M.(4,9);Luca, P.(10,11);Porta, C.(3,4);
Created: Friday, 14 July 2023, 10:43 AM
DOP37 Neoplastic lesions outside diseased area in inflammatory bowel disease patients: A national cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cremer1, P. Demetter2, M. De Vos3, J.F. Rahier4, F. Baert5, T. Moreels6, E. Macken6, E. Louis7, S. Vermeire8, D. Franchimont1, Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group

Created: Thursday, 30 January 2020, 10:12 AM
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Silvio Danese
Created: Friday, 14 July 2023, 2:22 PM
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Danese, S.(1)*;Abreu, M.T.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Charles, L.(4);Panaccione, R.(5);Afzali, A.(6);
Created: Friday, 14 July 2023, 10:43 AM
DOP37: Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies
Year: 2022
Source: ECCO'22
Authors: SCHREIBER, S.(1);Loftus Jr, E.V.(2);Maaser, C.(3);Danese, S.(4,5);Rudolph, C.(6);Jongen, R.(6);De Haas, A.(6);Oortwijn, A.(6);Vermeire, S.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP37: Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey
Year: 2021
Source: ECCO'21 Virtual
Authors: Král, J.(1);Nakov, R.(2);Lanska, V.(3);Barberio, B.(4);Benech, N.(5);Blesl, A.(6);Brunet, E.(7);Capela, T.L.(8);Derikx, L.A.A.P.(9);Dragoni, G.(10);Eek, A.(11);Frias-Gomes , C.(12);Gîlcă-Blanariu , G.E.(13);Gilroy, L.(14);Harvey, P.R.(15);Kagramanova, A.(16);Kani, H.T.(17);Konikoff, T.(18);Lessing, M.(19);Madsen, G.R.(20);Maksimaityte, V.(21);Miasnikova, M.(22);Mikolasevic, I.(23);Milivojevic, V.(24);Noviello, D.(25);Oliinyk, D.(26);Patai, A.(27);Protopapas, A.A.(28);Rodríguez-Lago, I.(29);Schreiber, P.(30);Skuja, V.(31);Tran, F.(19);Truyens, M.(32);Włodarczyk, M.(33);Zatorski, H.(34);Verstockt, B.(35);Segal, J.P.(36)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort Study
Year: 2020
Source: ECCO'20 Vienna
Authors: Anneline Cremer
Created: Tuesday, 23 June 2020, 5:40 PM
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort Study
Year: 2020
Source: ECCO'20 Vienna
Authors: Anneline Cremer
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1